Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for XCUR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 0.00
March 31, 2026 0.00
December 31, 2025 0.00
September 30, 2025 0.00
June 30, 2025 0.00
March 31, 2025 1.60M
December 31, 2024 12.40M
September 30, 2024 0.00
June 30, 2024 1.00M
March 31, 2024 0.00
December 31, 2023 -0.001M
September 30, 2023 -0.001M
June 30, 2023 -0.919M
March 31, 2023 4.595M
December 31, 2022 0.00
September 30, 2022 -0.002M
June 30, 2022 4.89M
March 31, 2022 -7.487M
Date Value
December 31, 2021 0.448M
September 30, 2021 -0.009M
June 30, 2021 0.131M
March 31, 2021 0.546M
December 31, 2020 0.138M
September 30, 2020 17.18M
June 30, 2020 0.15M
March 31, 2020 -2.333M
December 31, 2019 25.71M
September 30, 2019 58.58M
June 30, 2019 0.069M
March 31, 2019 -0.052M
December 31, 2018 -0.186M
September 30, 2018 20.26M
June 30, 2018 0.00
March 31, 2018 0.007M
December 31, 2017 8.37M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Tenax Therapeutics, Inc. 13.37M
Manhattan Scientifics, Inc. --
Century Therapeutics, Inc. 0.311M
Absci Corp. 102.73M
Celularity, Inc. 11.22M